Open Angle Glaucoma Market

Market Overview:

The 7 major open angle glaucoma markets reached a value of US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.69% during 2024-2034.

The open angle glaucoma market has been comprehensively analyzed in IMARC's new report titled "Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Open angle glaucoma refers to a chronic, irreversible, and progressive multifactorial optic neuropathy in which the pressure inside the eye increases. It is mainly characterized by an open angle of the anterior chamber, changes to the optic nerve head, and progressive loss of peripheral vision, followed by the loss of the central visual field. There aren't any noticeable indications of this ailment in the early stage, but in the advanced stage, the condition manifests as reduced vision, eye pain or pressure, a swollen or bulging cornea, redness in the white of the eye, rainbow-colored halos around lights, headaches, nausea, vomiting, etc. The diagnosis of open angle glaucoma typically requires a combination of the patient's clinical features, medical history, and eye examination. Other common assessment tools utilized to confirm a diagnosis include pachymetry, slit-lamp exam, gonioscopy, visual field and visual acuity tests, etc. The healthcare provider may also perform optical coherence tomography to detect changes in the optic nerve that may cause the disease.

The rising cases of eye disorders, which increase resistance in the drainage canals and damage the optic nerve, are primarily driving the open angle glaucoma market. Besides this, the growing prevalence of several associated risk factors, including advanced age, family history, obesity, systemic diseases like diabetes and hypertension, etc., is also augmenting the market growth. Furthermore, the widespread adoption of effective medications, such as alpha-2 adrenergic agonists and carbonic anhydrase inhibitors, which decrease aqueous production and enhance uveoscleral outflow, thereby providing symptom relief, is creating a positive outlook for the market. Apart from this, the inflating utilization of minimally invasive glaucoma surgery (MIGS), owing to its numerous advantages, including improved outflow of fluid from the eye and faster recovery with potentially fewer side effects than traditional surgeries, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of bimatoprost intracameral implant for treating the ailment, since it releases drugs directly to the targeted tissues and lowers intraocular pressure among patients, is expected to drive the open angle glaucoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the open angle glaucoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for open angle glaucoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the open angle glaucoma market in any manner.

Recent Developments:

• In May 2024, Sight Sciences, Inc. revealed the results of a large-scale, comparative real-world clinical outcomes study of patients treated with three leading minimally invasive glaucoma surgery (MIGS) technologies, which were published in the American Journal of Ophthalmology (AJO). The FDA had approved OMNI technology for canaloplasty and trabeculotomy to lower intraocular pressure (IOP) in adult patients with primary open-angle glaucoma.
• In March 2024, Nicox SA stated that the results of the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost for decreasing IOP in patients with open-angle glaucoma have been published in the peer-reviewed journal AJO.
• In December 2023, Glaukos announced that the FDA had approved a New Drug Application (NDA) for the iDose TR implant. The approval permits for iDose TR (travoprost intracameral implant) 75 mcg to be administered once per eye. The prostaglandin analog is indicated for the decrease of IOP in patients suffering from ocular hypertension or open-angle glaucoma.

Key Highlights:

• Approximately 57.5 million people worldwide are affected with primary open-angle glaucoma.
• Primary open-angle glaucoma (POAG) accounts for 12.3% of blindness worldwide.
• POAG affects 1.86% of adults over the age of 40.
• People in their seventies have a three to eight times higher prevalence of POAG.
• Open-angle glaucoma affects about 2 million people in the United States.

Drugs:

ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is intended for lowering increased IOP in individuals with open-angle glaucoma or ocular hypertension. The recommended dose is a single drop in the affected eye(s) once daily in the evening.

NCX 470 is a novel nitric oxide-donating bimatoprost eye drop designed to decrease intraocular pressure in people with open-angle glaucoma or ocular hypertension.

QLS-101 is a new ATP-sensitive potassium (KATP) channel modulator given as a topical eyedrop. QLS-101 addresses distal outflow resistance and episcleral venous pressure (EVP), which are important components of IOP. To reduce IOP, QLS-101 widens outflow channels and episcleral arteries in the eye distal to the trabecular meshwork.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the open angle glaucoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the open angle glaucoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current open angle glaucoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the open angle glaucoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the open angle glaucoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the open angle glaucoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of open angle glaucoma across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of open angle glaucoma by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of open angle glaucoma by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with open angle glaucoma across the seven major markets?
• What is the size of the open angle glaucoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of open angle glaucoma?
• What will be the growth rate of patients across the seven major markets?
   

Open Angle Glaucoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for open angle glaucoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the open angle glaucoma market?
• What are the key regulatory events related to the open angle glaucoma market?
• What is the structure of clinical trial landscape by status related to the open angle glaucoma market?
• What is the structure of clinical trial landscape by phase related to the open angle glaucoma market?
• What is the structure of clinical trial landscape by route of administration related to the open angle glaucoma market?